Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on Tuesday. Omvoh is now indicated for both forms of inflammatory bowel ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

Cartabuke: The biggest challenges in the treatment of Crohn’s disease include managing refractory disease, preventing and treating complications, and addressing the high cost of biologic therapies.

Bhat: I love this question! Crohn’s disease treatment has progressed significantly in recent years, incorporating new mechanisms of action such as interleukin inhibitors and Janus kinase ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests ...

Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. The company has also worked hard to diversify its pipeline. The stock is worth the premium. And that's before we get into ...